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Abstract
Aims In patients with heart failure and a pathologically prolonged PR interval, left ventricular (LV) filling can be improved by
shortening atrioventricular delay using His-bundle pacing. His-bundle pacing delivers physiological ventricular activation and
has been shown to improve acute haemodynamic function in this group of patients.
In the HOPE-HF (His Optimized Pacing Evaluated for Heart Failure) trial, we are investigating whether these acute haemody-
namic improvements translate into improvements in exercise capacity and heart failure symptoms.
Methods and results This multicentre, double-blind, randomized, crossover study aims to randomize 160 patients with PR
prolongation (≥200 ms), LV impairment (EF ≤ 40%), and either narrow QRS (≤140 ms) or right bundle branch block. All patients
receive a cardiac device with leads positioned in the right atrium and the His bundle. Eligible patients also receive a defibril-
lator lead. Those not eligible for implantable cardioverter defibrillator have a backup pacing lead positioned in an LV branch of
the coronary sinus. Patients are allocated in random order to 6 months of (i) haemodynamically optimized dual chamber
His-bundle pacing and (ii) backup pacing only, using the non-His ventricular lead.
The primary endpoint is change in exercise capacity assessed by peak oxygen uptake. Secondary endpoints include change in
ejection fraction, quality of life scores, B-type natriuretic peptide, daily patient activity levels, and safety and feasibility assess-
ments of His-bundle pacing.
Conclusions Hope-HF aims to determine whether correcting PR prolongation in patients with heart failure and narrow QRS
or right bundle branch block using haemodynamically optimized dual chamber His-bundle pacing improves exercise capacity
and symptoms. We aim to complete recruitment by the end of 2018 and report in 2020.
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Introduction
In patients with heart failure and a reduced ejection fraction,
a prolonged atrioventricular (AV) delay is associated with
increased mortality.1–3 Pacing is able to reduce a prolonged
AV delay; however, in patients with a narrow QRS, both right
ventricular and biventricular pacing can induce additional
ventricular dyssynchrony.4 His-bundle pacing however avoids
this as it activates the ventricles using the intrinsic conduc-
tion system.
STUDY DES IGN
© 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
ESC HEART FAILURE
ESC Heart Failure 2018; 5: 966–977
Published online 9 July 2018 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12315
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
Prolonged atrioventricular delay is pathological in
heart failure
Observational studies have found an association between a
prolonged PR interval and worse outcomes.5 In ischaemic
heart disease, patients with a long PR interval were found
to have a 58% higher mortality.5,6 In patients with heart
failure, PR prolongation also has an important prognostic
impact. For example, in the control arm of MADIT-CRT
(Multicenter Automatic Defibrillator Implantation Trial with
Cardiac Resynchronization Therapy), those patients with a
prolonged PR interval had a three-fold higher risk of death
or heart failure than those whose AV delay was within normal
limits.1
Prolonged atrioventricular delay can be a target
The concept of providing AV resynchronisation as a therapeu-
tic target in heart failure predates that of ventricular
resynchronisation.7,8 Suggestions that a prolonged AV delay
in heart failure is not only a prognostic marker but also a
therapeutic target comes from both acute haemodynamic
studies and an association with benefit found within random-
ized trials.
Shortening pathologically prolonged PR intervals has the
potential to improve cardiac function. PR prolongation
impairs LV filling,9 while reducing prolonged PR intervals
improves LV filling.10 In patients with left bundle branch block
(LBBB), optimizing left ventricular filling by shortening AV
delay using biventricular pacing acutely improves acute
cardiac function, as reflected by changes in LV dP/dtmax,
stroke volume, coronary artery flow, and systolic blood
pressure (SBP).11–13
Furthermore, data from large randomized trials of
biventricular pacing in patients with LBBB have found that
patients with prolonged native PR intervals appear to gain
greater benefit from biventricular pacing.14 In COMPANION,
patients with a long PR interval had a 17% greater relative
risk reduction in heart failure admissions and death
compared with those with a normal PR interval. Similarly, in
the MADIT-CRT trial, the prognostic benefits of biventricular
pacing appeared somewhat greater for participants with a
wide QRS of non-LBBB morphology when the PR interval
was prolonged.2
Right ventricular and biventricular pacing cause
ventricular dyssynchrony in patients with narrow
QRS
Both right ventricular pacing and biventricular pacing can be
used to treat a prolonged PR interval. However, both have
potential disadvantages.
Right ventricular pacing
Conventional right ventricular pacing had been used to
shorten prolonged PR intervals in small studies with mixed
results.7,15 However, conventional right ventricular pacing
prolongs left ventricular activation and therefore causes
dyssynchronous ventricular activation, which might offset
the beneficial effects of shortening PR interval. It is there-
fore unlikely to be the most efficient method for
delivering AV delay optimization in patients with heart
failure.
Biventricular pacing
Biventricular pacing might be a better option16 for deliver-
ing AV delay optimization. Biventricular pacing has trans-
formed the care of patients with reduced left ventricular
ejection fraction heart failure and a prolonged QRS
duration.17,18
The effects of biventricular pacing in patients without
QRS prolongation have also been explored,19,20 particularly
focusing on those with echocardiographic mechanical
dyssynchrony, because of the belief that biventricular pacing
delivers its benefit mainly through resynchronization of
ventricular wall contraction. However, when tested in a
bias-resistant manner, the results have not been favourable.
Biventricular pacing has been found to be harmful (the most
prominent trial showing an 81% increase in mortality) when
applied to this group of patients.20
One potential mechanism for harm is that when the native
QRS is narrow, biventricular pacing prolongs ventricular
activation time and therefore increases ventricular
dyssynchrony.4
Therefore, even biventricular pacing is an imperfect way to
deliver AV delay shortening, because some of the beneficial
effects may be offset by the non-physiological ventricular
activation.
His-bundle pacing
His-bundle pacing may be a better way to deliver AV delay
optimization in this group of patients. Permanent His-bundle
pacing allows the ventricles to be activated via the
His-Purkinje system. As a result, normal physiological cardiac
activation is maintained when His-bundle pacing is applied to
people with a narrow QRS duration.21 It may even restore
normal physiological activation in patients with right bundle
branch block (RBBB) or LBBB.22 Chronic His-bundle pacing
has been shown to be feasible and safe when used for brady-
cardia pacing (Figure 1).23
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Evidence that His-bundle pacing may be
beneficial in heart failure with prolonged
atrioventricular delay and narrow QRS
In patients with heart failure, a prolonged PR interval, and ei-
ther a narrow QRS or RBBB, AV delay optimization delivered
using His-bundle pacing has been shown to improve acute
haemodynamic function.24 While this is encouraging, longer
term outcome data are required before His pacing can be
routinely recommended as a method for pacing therapy for
heart failure in a group of patients who are not currently
targeted for treatment with biventricular pacing.
There is a precedent that haemodynamic changes translate
into better patient outcomes. The earliest evidence for bene-
fit from biventricular pacing in patients with heart failure
with LBBB was the clear and immediate improvement in
haemodynamics seen when pacing was initiated.8,25 Medium
term physiological studies subsequently demonstrated a
sustained effect with improved exercise capacity compared
with controls at up to 1 year.26 In turn, longer term trials
showed reduction in morbidity and mortality.17
Aim
The aim of HOPE-HF (His Optimized Pacing Evaluated for
Heart Failure) trial is to test whether the acute haemodynamic
effects observed with AV optimized His-bundle pacing in
patients with heart failure, a long intrinsic PR interval, and
narrow QRS or RBBB translate into an improvement in
exercise capacity, symptoms, and cardiac function.
Methods
Trial purpose
The HOPE-HF trial is designed to evaluate the effects of AV
optimized His-bundle pacing for patients with left ventricular
systolic dysfunction and PR prolongation but without LBBB.
The primary endpoint is the within-patient difference in
exercise capacity with His optimized pacing compared with
no pacing in a crossover trial with 6 month treatment pe-
riods. Secondary endpoints are quality of life (QOL), echocar-
diographic measurements, B-type natriuretic protein (BNP)
measurements, and daily patient activity levels.
Trial design
HOPE-HF is an investigator-initiated, UK-based, multicentre,
blinded, randomized, crossover trial of permanent AV opti-
mized His-bundle pacing. The planned recruitment is for
160 randomized patients across approximately 20 sites in
the UK.
Figure 1 Potential pacing methods for atrioventricular (AV) delay optimization. His-bundle pacing, biventricular (BiV) pacing, and right ventricular (RV)
pacing are all potential methods for shortening a pathologically long AV delay. His-bundle pacing does not prolong left ventricular activation time,
when applied to patients with a narrow QRS duration, whereas BiV pacing and RV pacing prolong left ventricular activation time.
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Inclusion and exclusion criteria
Study inclusion and exclusion criteria are shown in Table 1.
In brief, patients with symptomatic systolic heart failure
with an ejection fraction ≤ 40%, a PR interval ≥ 200 ms, and
either narrow QRS (≤140 ms) or RBBB of any duration are
eligible. The 140 ms QRS threshold arises from a meta-
regression of individual patient data from 3782 patients in
five trials.17 The evidence for biventricular pacing in patients
with a QRS duration <140 ms is less consistent.17
An additional requirement for patients with a left ventric-
ular ejection fraction between 36 and 40% is that they must
have a documented plasma BNP of >250 pg/mL within the
preceding 1 year.
Patients with permanent or persistent atrial fibrillation are
excluded because there is no opportunity for AV delay
optimization. Those with paroxysmal atrial fibrillation (with
sustained episodes lasting >24 h) are only eligible once treat-
ment to maintain sinus rhythm has been initiated and they
have remained in sinus rhythm for 6 months.
Intervention
Device implantation procedure
Permanent His-bundle pacing is attempted in all patients.
The trial is a multicentre study with device implantations
occurring at a number of different hospitals within the UK.
Implantation procedures are carried out by experienced
device implanters who as part of the trial were offered
training in His-bundle pacing.
His-bundle pacing is achieved using the active fixation
Medtronic Select Secure 3830 lead (Medtronic Inc.,
Minneapolis, MN, USA). The lead is delivered using either
the Medtronic C315 dedicated His delivery sheath or the
Medtronic C304 deflectable sheath (Medtronic Inc.). During
the implant procedure, a 12 lead electrocardiogram (ECG)
is continuously recorded to allow QRS duration and
morphology to be assessed. The electrogram from the His
pacing lead is displayed using either an electrophysiology
monitoring system or a Pace–Sense Analyser. The signal
from the lead is used to locate the His bundle. We target
a clear His potential followed by a ventricular signal,
which is at least double the size of the preceding atrial
signal (Figure 2).
If His-bundle pacing is unsuccessful, then a left ventricular
lead is implanted. The third lead is either a right ventricular
defibrillator lead, for patients with an implantable
cardioverter defibrillator (ICD) indication, or a left ventricular
coronary sinus lead, for those without an ICD indication. The
left ventricular lead was suggested by the funding review
committee so that a backup pacing lead is available should
it become clinically required and the His pacing lead becomes
non-functional or to provide backup pacing when the His lead
is programmed off (when in the non-treatment arm). All
patients receive a right atrial lead.
The generators used in the HOPE-HF trial are conventional
cardiac resynchronization therapy (CRT) pacemaker (CRT-P)
or CRT defibrillator devices.
Ventricular activation with His-bundle pacing
During His pacing, the theoretical physiological ideal is selec-
tive capture of the His-Purkinje system, so that ventricular ac-
tivation occurs purely via the native conduction system and
the resulting QRS is no wider than the native QRS with iden-
tical morphology. In patients with RBBB, His pacing may
shorten QRS duration due to recruitment of the right bundle
branch fascicles.
Non-selective His-bundle capture occurs when there is
capture of both the His bundle and the surrounding local
right ventricular myocardium close to the lead tip. Local
ventricular activation occurs while the His wave front is
travelling through the His-Purkinje system (prior to myocar-
dial breakout). This results in a pseudo-delta wave on the
surface ECG. The majority of ventricular activation occurs
rapidly via the His-Purkinje system. Overall, QRS duration
is prolonged slightly during non-selective capture, as a re-
sult of the early local myocardial activation; however, the
stimulation to end QRS time is not prolonged compared
with the His to end of QRS time, and reassuringly, left
ventricular activation time and pattern are not prolonged
with non-selective His capture.27 In the HOPE-HF trial, the
aim is to achieve His-bundle capture without prolongation
of left ventricular activation time. Therefore, we accept
either selective or non-selective capture. His capture is
confirmed using previously documented criteria28 and
summarized in Supporting Information, Table S1 and
illustrated in Figure 3.
Table 1 Inclusion and exclusion criteria (EF is left ventricular ejec-
tion fraction)
Inclusion criteria
Age over 18 years
EF ≤ 35% or EF 36–40% with BNP > 250 pg/mL
NYHA class II–IV
Sinus rhythm
PR interval ≥ 200 ms
QRS duration ≤ 140 ms or prolonged QRS duration with typical
RBBB morphology
Exclusion criteria
Permanent or persistent AF
Paroxysmal AF with history of sustained AF (≥24 h) in the
6 months prior to screening
Patients who are unable to perform cardiopulmonary exercise
testing
Lack of capacity to consent
Other serious medical condition with life expectancy of <1 year
Pregnancy
AF, atrial fibrillation; NYHA, New York Heart Association; RBBB,
right bundle branch block.
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Study endpoints
Primary endpoint
The primary endpoint of the trial is peak oxygen uptake mea-
sured during cardiopulmonary exercise testing. This endpoint
was selected because it is reproducible,29 a well-recognized
measure of cardiac function reserve, and a strong predictor
of mortality in heart failure.30 It has been used in many
previous trials of heart failure.
Secondary endpoints
Secondary endpoints include echo measurements of LV
volume, plasma concentration of BNP, QOL scores, daily
patient activity levels, and hospitalization episodes.
Endpoint measurements
Cardiopulmonary exercise testing
Patients exercise on a treadmill using a smoothed modified
Bruce protocol.29 Spirometry and gas exchange are moni-
tored using the COSMED Quark CPX System (Cosmed, Italy).
Exercise capacity is measured as peak oxygen consumption
(peak VO2) in mL/kg/min. Exercise time, VE/VCO2 slope, and
oxygen uptake efficiency slope are also measured.
Echocardiogram
Echocardiographic measurements are made using a Phillips
iE33 (Phillips, The Netherlands). The following variables are
measured: left ventricular dimensions, volumes and ejection
fraction, tissue-Doppler imaging, quantification of mitral re-
gurgitation, and maximum velocity through the aortic valve.
Pulsed-wave Doppler through the mitral valve is also
recorded for offline analysis of E-A waves for assessment of
AV filling patterns.
Quality of life
Quality of life is scored using both the Minnesota Living with
Heart Failure Questionnaire and the EQ-5D. The Minnesota
Living with Heart Failure Questionnaire is a validated
condition-specific measure with good sensitivity and discrim-
ination. It is complemented by the EQ-5D, which is a
validated generic measure of QOL, which enables comparison
of findings with other outcome studies. These are completed
by the patient. New York Heart Association assessment is
made by trial physicians.
Blood samples
Blood samples are taken for analysis of plasma BNP (Abbott
ARCHITECT immunoassay BNP, Abbott Laboratories, Abbott
Park, IL, USA).
Figure 2 (A) Intended area within right atrium for implantation of the His pacing lead. The target area is where the non-branching part of the His
bundle sits above the tricuspid valve on the right atrial—left ventricular part of the membranous septum. (B) Appearance of a single cardiac cycle re-
corded on an EP system, from a well-positioned His lead. Note that the atrial component (A) is less than half the size of the ventricular component (V).
There is a His signal (H) between the two. This appearance suggests a favourable location. (C) The electrogram can also be displayed using the Pace–
Sense Analyser. It is advisable to measure initially a unipolar signal utilizing the atrial channel with a gain setting of 0.05 mV/mm and a sweep speed of
50–100 mm/s. The ventricular channel is not sufficiently sensitive to detect His potentials. (D) This anterior–posterior projection radiographic image
shows the typical anatomical location for the His lead (labelled). (E) Rhythm strip showing successful His-bundle pacing. RV, right ventricular.
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Daily patient activity levels
Daily patient activity levels are automatically recorded by the
CRT device using an accelerometer. This gives a continuous
assessment of daily activity levels for the entire duration of
the study and has been shown to predict adverse cardiovas-
cular events.31
Implant data
Skin-to-skin time for device implantation is being recorded as
is total fluoroscopy duration. The delivery sheath utilized to
position the His lead is being noted, and lead measurements
including thresholds and sensing data for all leads are
recorded.
Follow-up location
All endpoint assessments and haemodynamic optimizations
(to determine the patient’s optimal paced and sensed AV
delays) are performed at the core centre (Imperial College
London). This is to ensure that investigations are carried out
within the required time frame of the study, measurement
variability is minimized by using the same equipment and
staff, and set-up and training costs are minimized.
Follow-up duration
The study endpoint measurements are conducted at three
set time points. Baseline measures are taken 2 months after
the device has been implanted (during which time no His pac-
ing is performed). The duration of each treatment arm is
6 months, to allow time for cardiac remodelling and to mini-
mize any carryover effect. Further endpoint assessments take
place 6 months after the baseline visit while patients have
had either His pacing programmed on or off and then after
a final 6 month interval following crossover to the alternate
arm. Assessment of adverse events is continuous throughout
the trial.
Figure 3 Differences between selective and non-selective His pacing. (A) Normal intrinsic conduction. The electrocardiographic imaging (Medtronic
Inc., Minneapolis, MN, USA) activation map shows rapid activation (each ventricle has homogenous colouring). (B) Selective His-bundle pacing.
Ventricular activation occurs solely via the His-Purkinje system, giving a normal QRS and normal activation map. The middle panel shows the short
delay between the pacing spike and the onset of ventricular activation. (C) Non-selective His-bundle pacing, during which ventricular activation occurs
via both local myocardial capture [seen as early activation in right ventricle (RV) (red colour)] and activation via the His-Purkinje system. Left ventricular
(LV) activation time and pattern is the same as during intrinsic activation and with selective His pacing because activation of the LV occurs via the
His-Purkinje system. AP, anterior-posterior orientation; LAD, left anterior descending; PA, posterior-anterior orientation.
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Patient flow
A flow chart outlining the study design is provided in Figure 4.
In brief, after device implantation, patients are programmed
to receive non-His bundle backup pacing [VVI 30 b.p.m. (or
DDI 30 b.p.m. if clinically indicated) utilizing either the right
ventricular or coronary sinus lead if implanted], ICD therapies
are enabled throughout the study in patients who have an
ICD implanted. The 2 month run in period allows patients
to recover from the implant procedure and ensures that the
His lead has integrated into the tissue prior to randomization.
Two months after implantation, study participants visit the
core centre to have baseline measurements recorded, which
includes all endpoint measurements. AV delay optimization is
performed using continuous non-invasive blood pressure.
Patients are then randomized to 6 months of AV optimized
His pacing or 6 months of no His pacing. At the end of each
6 month period, all the endpoints are measured. Patients
then enter the other arm of the study.
Randomization and allocation concealment
All patients have a commercially available CRT device im-
planted as part of the trial with a pacing lead permanently
positioned on the His bundle. After the initial 2 month period,
patients are randomized 1:1 to AV optimized His-bundle
pacing or no His pacing.
The study is double-blinded with patients, and the staff
conducting endpoint assessments both blinded to the pacing
treatment allocation. To ensure blinding is maintained, spe-
cial precautions are taken to prevent key staff from seeing
the ECG even during exercise testing.
Maintaining blinding during the trial
Atrioventricular optimization is performed at each study visit
by a member of staff blinded to treatment allocation. Before
the optimization process, a separate non-blinded staff mem-
ber programmes the device to His pacing in readiness for the
optimization. After the optimization, this non-blinded study
team member reprogrammes the device to either His pacing
on or His pacing off according to the treatment arm, using
the AV optimum determined by the blinded staff member
during optimization.
During cardiopulmonary exercise testing, it is essential to
monitor the ECG for patient safety. To ensure blinding is
maintained, two members of the trial team are always pres-
ent during a patient’s test—one is blinded and the other
not. The blinded member of the team leads the test but is
not able to see the ECG. The role of the non-blinded trial
Figure 4 Patient study flow chart (AV, atrioventricular; BNP, B-type natriuretic protein; ICD, implantable cardioverter defibrillator; QOL, quality of life).
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team member is to observe the ECG for arrhythmias that
would necessitate the test be stopped for safety reasons.
The unblinded member does not communicate with the
patient or the blinded member unnecessarily.
Echocardiography is performed and analysed by a blinded
member of staff. No ECG is recorded during the procedure.
Pacing checks are only conducted by a designated unblinded
investigator.
Design of the atrioventricular delay
haemodynamic optimization protocol
In this study, we use non-invasive acute haemodynamic
measurements to identify the optimal paced and sensed AV
delays for individual patients.
In order to minimize the effect of noise, and so minimize
the uncertainty of the optimization, we use the repeated
alternation and parabolic fitting method. This approach has
been shown to have a high level of reproducibility for deter-
mining the AV delay optimum. It has been described in detail
previously and uses continuous non-invasive beat-by-beat
blood pressure using the Finapres Nova device (Finapres
Medical Systems, The Netherlands).32 Briefly, continuous
non-invasive beat-by-beat blood pressure is recorded using
the Finapres Nova device. Each tested AV delay is compared
with a reference setting, and mean relative change in SBP is
then calculated as the difference between the mean SBP at
the reference setting (8 beats at the reference setting imme-
diately before the transition) and the mean SBP at the tested
setting (8 beats immediately after the transition to the tested
AV delay). A minimum of six alternations are performed be-
tween the reference setting and atrial synchronous dual
chamber His pacing and the mean of these alternations used
to calculate the mean relative change for a particular
programmed AV delay compared with the reference setting.
For sensed AV delay, the reference setting is sinus rhythm.
For the atrial paced AV delay, the reference setting is AAI
pacing at 10 b.p.m. above the patient’s intrinsic rate.
The following programmed AV delays are tested: 40, 80,
120, 160, 200, 240, 280, and 320 ms, but the protocol is
stopped if intrinsic ventricular activation occurs before
320 ms. Figure 5 demonstrates the AV optimization process.
Analysis plan
All study data are being recorded in our institution’s clinical
trial database (Inform, version 4.6). The trial is conducted
through the Imperial College Clinical Trials Unit, which
provides monitoring and trial oversight to minimize the
amount of missing data.
The primary endpoint is peak oxygen uptake measured
using cardiopulmonary exercise testing. The primary outcome
will be analysed using a two-level hierarchal model. We will
include treatment, period, and sequence effect within the
model. Random subject effects will also be included in the
regression model if appropriate. Differences in secondary
outcomes will also be analysed using a two-level hierarchal
model. Normality will be checked, and appropriate transfor-
mation or non-parametric methods will be used if it is
not met.
Planned subgroup analysis
Right bundle branch block cohort
We expect one-third of recruited patients to have RBBB. In
these patients, His-bundle pacing may shorten QRS
duration by overcoming the RBBB (Supporting Information,
Figure S1). Therefore, patients may theoretically obtain ben-
efit from ventricular resynchronization in addition to that ob-
tained from optimization of AV delay. Narrowing of QRS may
occur by (i) positioning the pacing lead distal to the site of
bundle branch block leading to an electrical bypass of the
block; (ii) overcoming the block with sufficient stimulus to ac-
tivate distal dormant tissue, relying on either source–sink re-
lationships during pacing vs. intrinsic impulse propagation or
the virtual electrode polarization effects or (iii) retrograde ac-
tivation via capture of an upper septal branch of the His-
Purkinje system or (iv) in the case of non-selective His-bundle
capture partial or full correction of the terminal RBBB pattern
by fusion without recruiting the RBB fascicles.
We will perform a subgroup analysis to test for the possi-
bility that RBBB patients show a larger benefit than the
narrow QRS patients, which might signify the presence of
dual benefit in bundle branch block patients.
PR interval
We will test whether there is a relationship between magni-
tude of improvement in the outcome measures with AV opti-
mized His pacing and baseline PR interval. Such a relationship
might be expected if there is a benefit from PR interval
shortening. The PR interval of 200 ms or above was chosen
as the entry for the HOPE-HF because in the COMPANION
trial, patients with a PR interval longer than 200 ms appeared
to obtain greater benefit from CRT.33 However, the MADIT-
CRT study reported a larger difference in those whose PR
interval was >230 ms2; we wanted to recruit a broad range
of patients who might permit later evaluation of the effect
of PR interval.
E-A wave analysis
We will test whether the presence of E-A wave fusion
predicts the size of any His pacing benefit.
Baseline E-A wave fusion on echocardiography suggests
that there is inefficient left ventricular filling, and it is possible
that it may be useful in selecting patients who are likely to
benefit from AV optimization with His pacing.
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Selective vs. non-selective His capture
If there are significant numbers of patients with non-selective
His capture, we will perform an analysis to assess whether
the type of His capture affects the outcome measures.
Sample size calculation
The smoothed modified Bruce protocol in patients with heart
failure has a test–retest variability of 2.4 mL/kg/min.29 Im-
plantation of a CRT-P in patients with broad QRS duration
and heart failure results in a 0.5–2.5 (mean 1.5) mL/kg/min
increase in peak oxygen uptake.34,35 Acute haemodynamic
data suggest that the benefit from His-bundle pacing in long
PR narrow QRS patients is around 60% of the effect seen with
CRT in LBBB patients.24 We might therefore expect that the
estimated increment in peak oxygen uptake of 60% would
be 0.9 mL/kg/min. One hundred and twenty six patients
would give 90% power at the 5% significance level to detect
a 0.7 mL/kg/min change. To account for combined mortality
and dropout rates as high as 21%, we will recruit 160
patients.
Compliance and loss to follow-up
It is anticipated that some patients may request a change in
their treatment arm, particularly if there is a change in their
symptom status. If this occurs, we will try to encourage pa-
tients to continue with their designated treatment until they
cross over or complete the study as scheduled. If however
the clinical team judges that it is necessary to turn on or off
His pacing, this will be performed. Analysis will be on the
standard intention to treat basis.
Follow-up will be coordinated and carried out by a re-
search team dedicated to this study. If patients decide they
no longer wish to attend the core centre for follow-up, then
we will ask if they are willing at least to be contacted by
Figure 5 Atrioventricular (AV) delay optimization protocol. The relative change in systolic blood pressure (SBP) between 8 beats of AAI pacing and 8
beats of dual chamber atrial synchronous–His pacing at a given atrioventricular delay (AVD) is determined [AV delay = 80 ms in this example (top left)].
This is a single alternation (plotted bottom left). A minimum of six alternations are made for each AVD (middle sections top and bottom). This process
is repeated for each AV delay between 40 and 320 ms (less if intrinsic AV conduction occurs before 320 ms). The optimal AV delay is then derived from
the plotted parabola (bottom right). In this example, the optimal AV delay was 160 ms. BP, blood pressure; ECG, electrocardiogram.
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the research team to ensure data on adverse events can be
recorded.
Steering committee
This committee is responsible for developing and monitor-
ing the implementation of the protocol. The committee is
supported by a statistician independent of the sponsor
and is responsible for ensuring timely publication of the
results.
Data Safety Monitoring Board
The Data Safety Monitory Board (DSMB) is responsible for
monitoring patient safety and will recommend that the trial
is stopped prematurely if a significant increase in all-cause
mortality is noted in the active His pacing arm. The DSMB
may request interim analyses should the safety data
indicate that treatment is associated with important adverse
events.
Adverse events
All adverse events will be documented and reviewed by the
study-specific DSMB. Serious adverse events are defined as
those which are not anticipated or not known to be related
to the condition being studied or the intervention being used
that would result in any of the following outcomes: death,
life-threatening condition, unexpected/unplanned inpatient
hospitalization, and persistent or significant disability or
incapacity.
Timeline
Recruitment began in January 2016 and is expected to com-
plete by the end of 2018. Follow-up is therefore expected
to end by approximately the end of 2019 and the trial to
report in 2020.
Discussion
If AV optimized His pacing is found to deliver clinical benefits
to patients with heart failure and a long PR interval without
LBBB, this procedure may become a new therapeutic option
for this population of highly symptomatic patients. Pacing
therapy for heart failure is not currently indicated for this
population of patients; UK data suggest that they form
approximately 20% of all heart failure patients.5
A positive result from this trial would provide randomized
controlled evidence of physiological benefit of His-bundle
pacing in these patients.
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Figure S1. (A) Normal ventricular activation, with activation
travelling from the AV node down the Bundle of His and then
into the Left and Right Bundle Branches. This illustration
demonstrates that fibres within the bundle of His are already
predestined for their respective Bundle Branches. (B) Proxi-
mal site of RBBB, (C) a pacing lead has been positioned in a
site distal to this block allowing an electrical bypass of the
RBBB and thus reversing the electrical abnormality. (D) Distal
site of RBBB (unfeasible for pacing lead to be positioned dis-
tal to this). (E) Remote electrical activation with a proximally
placed lead could reverse this electrical abnormality. This
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could occur (1) because of high pacing outputs, (2) as a con-
sequence of the source-sink-theory and a high likelihood of
their being diseased fibres already in the proximal location
or (3) the virtual electrode polarization theory. (F) Highlights
that each bundle branch has multiple branches. (G) A high
septal branch may fortuitously be activated with a conven-
tionally placed His lead. This could result in retrograde activa-
tion down the branch back to a place in the bundle branch
which is distal to the site of block allowing antegrade activa-
tion from this site forward.
Table S1. Summary characteristics of selective and non-
selective his bundle pacing.
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